2014
DOI: 10.1016/j.beem.2014.02.001
|View full text |Cite
|
Sign up to set email alerts
|

The role of radioiodine therapy in benign nodular goitre

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
30
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 27 publications
(30 citation statements)
references
References 90 publications
0
30
0
Order By: Relevance
“…Several recent articles [77] have indicated that these adverse effects are probably dose-dependent and are negligible with lower rhTSH doses. According to Bonnema et al [77], the optimal dose of rhTSH to improve radioiodine therapy is most likely in the range of 0.03-0.1 mg.…”
Section: Recombinant Human Tsh-stimulated Radioiodine Therapymentioning
confidence: 97%
See 2 more Smart Citations
“…Several recent articles [77] have indicated that these adverse effects are probably dose-dependent and are negligible with lower rhTSH doses. According to Bonnema et al [77], the optimal dose of rhTSH to improve radioiodine therapy is most likely in the range of 0.03-0.1 mg.…”
Section: Recombinant Human Tsh-stimulated Radioiodine Therapymentioning
confidence: 97%
“…This problem may be solved by increasing the radioiodine uptake (RAIU) in such nodular goiters [77]. For this purpose, recent studies using rhTSH in preparation for radioiodine therapy have shown good results [78].…”
Section: Recombinant Human Tsh-stimulated Radioiodine Therapymentioning
confidence: 99%
See 1 more Smart Citation
“…11,12 In the past decades, treatment with radioactive iodine has also been employed leading to a 35-50% reduction in goiter volume. 13 Thyroid hormone suppressive therapy for individuals with thyroid nodules is optional, but as there is no agreement on the efficacy and safety of this method, its routine use is not recommended.…”
Section: Introductionmentioning
confidence: 99%
“…In contrast, the accumulation of radioisotopes in labeled cells can be potentially destructive, as it is for thyroid cells treated with radioiodine. 5,6 Despite the drawbacks, radioisotopes are actively involved in stem cell tracking both in the preclinical setting and in clinical trials. 7,8 Radioisotopes can be used for direct labeling of cells, but also can be conjugated with ligands of specific receptors present in a particular type of cell.…”
Section: Introductionmentioning
confidence: 99%